This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Research
Haijun Yu
Wuhan University Zhongnan Hospital
Corresponding Author
ORCiD: https://orcid.org/0000-0003-1943-2770
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: TREM2 was identified as a marker for tumor-associated macrophages (TAMs) and monocytes. However, there is limited information concerning the TREM2 mRNA levels correlated with the outcome and tumor-infiltrating lymphocytes in different cancers.
Methods: To explore the expression pattern and prognostic value of TREM2 in pan-cancer, We use multiple databases, including ONCOMINE, PrognoScan, Kaplan-Meier Plotter, GEPIA, and TIMER. we investigated the correlations between TREM1 expression and immune infiltration in cancers, especially kidney renal papillary cell carcinoma (KIRP), and liver hepatocellular carcinoma (LIHC)
Results: According to the results from Oncomine and TIMER datasets, in a general way, TREM2 mRNA expression is higher in the majority of the tumor and is lower in lung cancer, compared with normal adjacent tissues. A high expression level of TREM2 was beneficial to the survival of LIHC patients. Both in KIRP and LIHC, TREM2 expression levels showed significant positive correlations with infiltrating levels of macrophages and dendritic cells. It also correlated with diverse immune marker sets. We can also find that TREM2 expression was modestly associated with CD8+T cells in KIRP. However, it is related to the Treg in LIHC.
Conclusions: TREM2 may be a prognostic marker in the multitudinous tumor. Furthermore, TREM2 may interact with immune infiltration to influence patient survival in cancers like LIHC and KIRP.
Keywords
TREM2, kidney renal papillary cell carcinoma (KIRP), prognosis, immune infiltrates
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
This is a list of supplementary files associated with this preprint. Click to download.
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 16 Feb, 2021
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Translational Medicine
Learn more about our company.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Research
Haijun Yu
Wuhan University Zhongnan Hospital
Corresponding Author
ORCiD: https://orcid.org/0000-0003-1943-2770
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 16 Feb, 2021
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Translational Medicine
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: TREM2 was identified as a marker for tumor-associated macrophages (TAMs) and monocytes. However, there is limited information concerning the TREM2 mRNA levels correlated with the outcome and tumor-infiltrating lymphocytes in different cancers.
Methods: To explore the expression pattern and prognostic value of TREM2 in pan-cancer, We use multiple databases, including ONCOMINE, PrognoScan, Kaplan-Meier Plotter, GEPIA, and TIMER. we investigated the correlations between TREM1 expression and immune infiltration in cancers, especially kidney renal papillary cell carcinoma (KIRP), and liver hepatocellular carcinoma (LIHC)
Results: According to the results from Oncomine and TIMER datasets, in a general way, TREM2 mRNA expression is higher in the majority of the tumor and is lower in lung cancer, compared with normal adjacent tissues. A high expression level of TREM2 was beneficial to the survival of LIHC patients. Both in KIRP and LIHC, TREM2 expression levels showed significant positive correlations with infiltrating levels of macrophages and dendritic cells. It also correlated with diverse immune marker sets. We can also find that TREM2 expression was modestly associated with CD8+T cells in KIRP. However, it is related to the Treg in LIHC.
Conclusions: TREM2 may be a prognostic marker in the multitudinous tumor. Furthermore, TREM2 may interact with immune infiltration to influence patient survival in cancers like LIHC and KIRP.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
This is a list of supplementary files associated with this preprint. Click to download.
Loading...